KalVista Pharmaceuticals
KALV
KALV
93 hedge funds and large institutions have $459M invested in KalVista Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 22 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
2.9% more ownership
Funds ownership: 105.42% → 108.32% (+2.9%)
8% less funds holding
Funds holding: 101 → 93 (-8)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Holders
93
Holding in Top 10
4
Calls
$21.3M
Puts
$11.3M
Top Buyers
| 1 | +$14.4M | |
| 2 | +$8.51M | |
| 3 | +$7.32M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$4.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$4.25M |
Top Sellers
| 1 | -$8.67M | |
| 2 | -$5.57M | |
| 3 | -$4.31M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.29M |
| 5 |
First Manhattan
New York
|
-$3.78M |